I dont see Vitiglio on Ohms list, yet. Skip if you hate ai.
I dont even know if its correct
If anyones bored
A Comprehensive Review on Vitiligo: Pathogenesis, Classification, Biomarkers, and Therapeutic Approaches
Key Findings Connecting CCR5 to Vitiligo
The CCL5-CCR5 Elevator: A recent meta-analysis highlighted in the paper shows that patients with active vitiligo have significantly elevated levels of the chemokine CCL5 in their skin. CCL5 binds with the highest affinity to the CCR5 receptor on immune cells.
Treg Dysfunction and Skin Depigmentation: In vitiligo, the immune system mistakenly attacks skin-pigmenting melanocytes. The study notes that CCR5 expression is heavily elevated on regulatory T cells (Tregs) in vitiligo lesions. This indicates that the CCL5-CCR5 axis drives dysfunctional Tregs to promote localized skin depigmentation.
A New Treatment Frontier: The study explicitly concludes that focusing on and blocking the CCL5-CCR5 axis may offer novel therapeutic strategies to restore immune function and stop the progression of vitiligo.
Direct Implications for Leronlimab
This paper establishes that leronlimab's mechanism of action is applicable to a completely new multibillion-dollar autoimmune dermatology market:
Expanding the Platform Indication: Just as leronlimab blocks CCL5 to stop tumor cell migration and macrophage recruitment in oncology, it can theoretically be deployed here to shut down the homing of destructive, dysfunctional Tregs to healthy skin tissue.
Synergy with Current Breakthroughs: The review notes that newly developed Janus kinase (JAK) inhibitors are currently the leading targeted immunotherapies used to promote repigmentation. Because leronlimab targets an entirely different structural entryway (the chemokine axis rather than internal JAK/STAT transcription), it represents an ideal candidate to pair with JAK inhibitors for a more comprehensive combination treatment.
Safety Advantage Over Systemic Steroids: The study highlights that current primary treatments, like long-term topical corticosteroids, cause severe side effects like skin atrophy and accidental localized depigmentation. Leronlimab's proven subcutaneous safety profile provides a clean, targeted alternative.
https://www.ijpsjournal.com/assetsbackoffice/...ches.-.pdf
I dont even know if its correct
If anyones bored
A Comprehensive Review on Vitiligo: Pathogenesis, Classification, Biomarkers, and Therapeutic Approaches
Key Findings Connecting CCR5 to Vitiligo
The CCL5-CCR5 Elevator: A recent meta-analysis highlighted in the paper shows that patients with active vitiligo have significantly elevated levels of the chemokine CCL5 in their skin. CCL5 binds with the highest affinity to the CCR5 receptor on immune cells.
Treg Dysfunction and Skin Depigmentation: In vitiligo, the immune system mistakenly attacks skin-pigmenting melanocytes. The study notes that CCR5 expression is heavily elevated on regulatory T cells (Tregs) in vitiligo lesions. This indicates that the CCL5-CCR5 axis drives dysfunctional Tregs to promote localized skin depigmentation.
A New Treatment Frontier: The study explicitly concludes that focusing on and blocking the CCL5-CCR5 axis may offer novel therapeutic strategies to restore immune function and stop the progression of vitiligo.
Direct Implications for Leronlimab
This paper establishes that leronlimab's mechanism of action is applicable to a completely new multibillion-dollar autoimmune dermatology market:
Expanding the Platform Indication: Just as leronlimab blocks CCL5 to stop tumor cell migration and macrophage recruitment in oncology, it can theoretically be deployed here to shut down the homing of destructive, dysfunctional Tregs to healthy skin tissue.
Synergy with Current Breakthroughs: The review notes that newly developed Janus kinase (JAK) inhibitors are currently the leading targeted immunotherapies used to promote repigmentation. Because leronlimab targets an entirely different structural entryway (the chemokine axis rather than internal JAK/STAT transcription), it represents an ideal candidate to pair with JAK inhibitors for a more comprehensive combination treatment.
Safety Advantage Over Systemic Steroids: The study highlights that current primary treatments, like long-term topical corticosteroids, cause severe side effects like skin atrophy and accidental localized depigmentation. Leronlimab's proven subcutaneous safety profile provides a clean, targeted alternative.
https://www.ijpsjournal.com/assetsbackoffice/...ches.-.pdf
6
